Our platform integrates generative or predictive powers of AI with extensive human knowledge in biologics drug design and continuously improves its performance based on proprietary databases.
PLATFORM
Best-in-class biologics discovery platform
- 01 OVERVIEW
Our platform enables rapid design and optimization of potential best-in-class biologics to transform the treatment landscape for a broad spectrum of human diseases.
With substantial crowding around a limited set of biological mechanisms, there is an unprecedented need for generating best-in-class candidates with transformative differentiation. Yet conventional computational and wet-lab workflows continue to fall short in delivering the necessary quality, speed, and consistency.
Ailux has built an end-to-end discovery platform delivering high-quality therapeutic candidates. Leveraging novel modality design, our platform unlocks multi-parametric exploration of best-in-class profiles without compromise, setting a new standard for advanced biologics discovery.
- 02 DIFFERENTIATION
Unique approach for best-in-class design
Unparalleled intelligence integration
Thorough platform validation
We diligently de-risk our platform in wholly-owned internal projects and consistently benchmark its performance head-to-head with traditional approaches.
Turning innovation into practical impact
Our platform has the proven ability to tackle complex and challenging problems, including multi-objective discovery, next-gen engineering, and advanced modalities, which in turn spurs further rounds of innovation.
- 03 APPLICATION
How do we create unique value with AI?
Challenging Target
- GPCR
- Ion channel
- Conditional binding
Multi-Parametric Optimization
- Guided by structure modeling
- Parallel optimization
- Fewer and more efficient design cycles
Multispecific Design
- Bispecific engineering
- Trispecific immune cell engager
- Format optimization
- 04 ENGINE
Industry-leading AI/ML models for advanced drug design
Protein complex structure prediction
- Bridges the 1D and 3D protein space through deep learning
- Unravel antibody–antigen interaction with high accuracy at scale
- Unlocks novel downstream applications
Generative AI design for protein-based therapeutics
- Proprietary generative LLM for proteins
- Generates highly-developable protein/antibody sequence
- Conditional generation to the desired profile
Predictive AI suite for multi-parametric evaluation
- Comprehensive computational suite dedicated to biologics
- Pre-trained on a proprietary database significantly larger than what’s publicly available
- Harnesses the power of active learning to refine project-specific models
- 05 DATABASE
AtlaX Database
Proprietary multi‑modal
biologics database
biologics database
- Curated through specialized high-throughput techniques
- Carefully balanced with negative results
- Boosting model performance with the scaling law
Data highlights
~ 5x
More paired antibody sequences than OAS
200+
Epitope data for antibody-antigen pairs
~ 45%
More unpaired antibody sequences than OAS
~ 4.5x
More protein complex structures than SabDab
15K+
Antibody-antigen sequence pairs sourced from patents
~ 10x
Developability dataset compared to the literature
- Data as of March 2025
- 06 PARTNERING
Innovate together to build transformative medicines.
